midazolam and itraconazole

midazolam has been researched along with itraconazole in 46 studies

Research

Studies (46)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (15.22)	18.2507
2000's	13 (28.26)	29.6817
2010's	18 (39.13)	24.3611
2020's	8 (17.39)	2.80

Authors

Authors	Studies
Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA	1
Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A	1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Andricopulo, AD; Moda, TL; Montanari, CA	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Dalvie, D; Loi, CM; Smith, DA	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Backman, JT; Neuvonen, PJ; Olkkola, KT	1
Ahonen, J; Neuvonen, PJ; Olkkola, KT	2
Backman, JT; Kivistö, KT; Neuvonen, PJ; Olkkola, KT	1
Iga, T; Kotaki, H; Sawada, Y; Yamamoto, K; Yamano, K	1
Backman, JT; Kivistö, KT; Neuvonen, PJ; Taavitsainen, P; Wang, JS; Wen, X	1
Balian, JD; Flockhart, DA; Yuan, R	1
Iga, T; Katashima, M; Kotaki, H; Matsuo, H; Ohtani, H; Sawada, Y; Takedomi, S; Yamamoto, K; Yamano, K	1
Cho, JY; Chung, JY; Hong, KS; Jang, IJ; Kim, JR; Lim, HS; Liu, KH; Oh, DS; Shin, JG; Shin, SG; Yi, SY; Yu, KS	1
Calamia, JC; Glodowski, M; Huang, W; Isoherranen, N; Lin, YS; McConn, DJ; Thummel, KE; Totah, RA	1
Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, PJ	1
Edginton, AN; Jang, IJ; Niederalt, C; Sevestre, M; Vossen, M; Willmann, S	1
Iwaki, H; Iwakiri, K; Kaneshiro, Y; Masada, T; Oda, Y; Ohashi, H; Takaoka, K	1
Davis, C; Isoherranen, N; Kunze, KL; Peng, CC; Templeton, I; Thummel, KE	1
Isoherranen, N; Kunze, KL; Liu, JO; Lutz, JD; Nelson, WL; Peng, CC; Shi, W	1
Chang, SY; Grubb, MF; Isoherranen, N; Peng, CC; Rodrigues, AD; Shirasaka, Y; Thummel, KE	1
Aarons, L; Johnson, TN; Ogungbenro, K; Rostami-Hodjegan, A; Salem, F; Vajjah, P	1
Bulliot, C; Mentré, V	1
Budha, N; Chen, Y; Hop, CE; Jin, JY; Kenny, JR; Lu, T; Ma, F; Mao, J; Wong, H	1
Annaert, P; de Hoon, J; de Loor, H; Knops, N; Kuypers, DRJ; Vanhove, T	1
Ericsson, H; Janzén, D; Kanebratt, KP; Lennernäs, H; Lundahl, A; Prieto Garcia, L	1
Britz, H; Eissing, T; Frechen, S; Hanke, N; Lehr, T; Moj, D; Wendl, T	1
Cho, JY; Jang, IJ; Kim, AH; Kim, B; Lee, J; Lee, S; Yi, S; Yoon, SH; Yu, KS	1
Bairlein, M; Denner, K; Fricke, R; Gieschen, H; Graudenz, K; Korjamo, T; Koskinen, M; Prien, O; von Bühler, CJ; Wilkinson, G; Zurth, C	1
Cahn, AP; Georgiou, A; Harrell, AW; Hessel, EM; Marotti, M; Patel, A; Riddell, K; Taskar, KS; Taylor, M; Tracey, H; Wilson, R	1
Burke, W; Cantarini, M; Frewer, P; Goldwater, R; Han, D; Hara, I; Li, Y; Ren, S; Scarfe, G; Schalkwijk, S; Vishwanathan, K	1
Beelen, A; Curd, L; Goti, V; Horton, JK; Li, C; Sale, M; Tao, W	1
Abdulrasool, LI; Endres, CJ; Lee, A; Mayor, JG; Rustia, EL; Sun, H; Topletz-Erickson, A; Walker, L	1
Biermer, M; Biewenga, J; Hillewaert, V; Kakuda, TN; Nangosyah, J; Palmer, M; Rasschaert, F; Snoeys, J; Talloen, W; Vandenbossche, J; Yogaratnam, J	1
Barth, A; Brimhall, DB; Dumont, EF; Nguyen, D; Perry, CR; Shabbir, S; Srinivasan, M; Swift, B; Thomas, S; Zamek-Gliszczynski, MJ	1
Benhadji, KA; Gao, L; He, Y; Hunt, A; Mina, M; Sonnichsen, D; Takenaka, T; Yamamiya, I	1
Bergagnini-Kolev, M; Curran, AK; Kane, K; Templeton, IE	1

Reviews

2 review(s) available for midazolam and itraconazole

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. Journal of clinical pharmacology, 1999, Volume: 39, Issue:11 Topics: Alprazolam; Anti-Anxiety Agents; Data Collection; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Humans; Itraconazole; Ketoconazole; Midazolam; Triazolam	1999

Trials

12 trial(s) available for midazolam and itraconazole

Article	Year
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clinical pharmacology and therapeutics, 1994, Volume: 55, Issue:5 Topics: Adult; Analysis of Variance; Cytochrome P-450 Enzyme Inhibitors; Double-Blind Method; Drug Synergism; Female; Humans; Itraconazole; Ketoconazole; Male; Midazolam; Psychomotor Performance; Reference Values	1994
Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. British journal of clinical pharmacology, 1995, Volume: 40, Issue:3 Topics: Administration, Oral; Adult; Drug Interactions; Enzyme Inhibitors; Female; Humans; Itraconazole; Male; Midazolam; Naphthalenes; Terbinafine; Time Factors; Volunteers	1995
The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesthesia and analgesia, 1996, Volume: 82, Issue:3 Topics: Administration, Oral; Adult; Antifungal Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Fluconazole; Humans; Hypnotics and Sedatives; Injections, Intravenous; Itraconazole; Male; Metabolic Clearance Rate; Midazolam; Placebos; Psychomotor Performance	1996
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. European journal of clinical pharmacology, 1998, Volume: 54, Issue:1 Topics: Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Hypnotics and Sedatives; Itraconazole; Male; Midazolam; Oxidoreductases, N-Demethylating; Rifampin	1998
Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clinical pharmacology and therapeutics, 2010, Volume: 88, Issue:4 Topics: Adult; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Inhibitory Concentration 50; Itraconazole; Male; Metabolic Clearance Rate; Midazolam; Young Adult	2010
In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation. Basic & clinical pharmacology & toxicology, 2019, Volume: 124, Issue:1 Topics: Administration, Oral; Adult; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Delayed-Action Preparations; Drug Interactions; Healthy Volunteers; Humans; Itraconazole; Male; Metabolic Clearance Rate; Midazolam; Prospective Studies; Tacrolimus; Young Adult	2019
Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers. Drug metabolism and pharmacokinetics, 2019, Volume: 34, Issue:4 Topics: Adult; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Itraconazole; Ketoconazole; Male; Midazolam; Rifampin; Young Adult	2019
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies. European journal of drug metabolism and pharmacokinetics, 2019, Volume: 44, Issue:6 Topics: Aged; Cells, Cultured; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Enzyme Induction; Female; Humans; Itraconazole; Male; Membrane Transport Proteins; Microsomes, Liver; Midazolam; Middle Aged; Pyrazoles; Rifampin; Rosuvastatin Calcium	2019
Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations. Drug metabolism and disposition: the biological fate of chemicals, 2020, Volume: 48, Issue:4 Topics: Administration, Inhalation; Adolescent; Adult; Aged; Area Under Curve; Clarithromycin; Computer Simulation; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Erythromycin; Healthy Volunteers; Humans; Indazoles; Indoles; Itraconazole; Male; Microsomes, Liver; Midazolam; Middle Aged; Models, Biological; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Prospective Studies; Retrospective Studies; Young Adult	2020
Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer. Clinical drug investigation, 2022, Volume: 42, Issue:8 Topics: Area Under Curve; Drug Interactions; Healthy Volunteers; Humans; Itraconazole; Lung Neoplasms; Metformin; Midazolam; Prospective Studies; Pyrimidines; Pyrroles; Rifampin; Topotecan	2022
Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir). Clinical pharmacology in drug development, 2022, Volume: 11, Issue:12 Topics: Adult; Antiviral Agents; Capsid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Ethinyl Estradiol; Female; Hepatitis B virus; Humans; Itraconazole; Midazolam	2022
Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data. The AAPS journal, 2023, 06-21, Volume: 25, Issue:4 Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Itraconazole; Midazolam; Models, Biological	2023

Other Studies

32 other study(ies) available for midazolam and itraconazole

Article	Year
Rational use of in vitro P-glycoprotein assays in drug discovery. The Journal of pharmacology and experimental therapeutics, 2001, Volume: 299, Issue:2 Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera	2001
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. Journal of medicinal chemistry, 2003, Apr-24, Volume: 46, Issue:9 Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine	2003
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics. Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5 Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution	2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics	2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Which metabolites circulate? Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5 Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations	2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver. Drug metabolism and disposition: the biological fate of chemicals, 1999, Volume: 27, Issue:3 Topics: Animals; Antifungal Agents; Blood Proteins; Hypnotics and Sedatives; Itraconazole; Ketoconazole; Male; Microsomes, Liver; Midazolam; Predictive Value of Tests; Protein Binding; Rats; Rats, Sprague-Dawley	1999
Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacology & toxicology, 1999, Volume: 85, Issue:4 Topics: Antifungal Agents; Biotransformation; Calcium Channel Blockers; GABA Modulators; Humans; Hydroxylation; Itraconazole; Ketoconazole; Male; Microsomes, Liver; Midazolam	1999
Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug metabolism and disposition: the biological fate of chemicals, 2001, Volume: 29, Issue:4 Pt 1 Topics: Anesthetics, Intravenous; Animals; Aryl Hydrocarbon Hydroxylases; Cimetidine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Erythromycin; Humans; Intestinal Absorption; Itraconazole; Kinetics; Liver; Male; Microsomes, Liver; Midazolam; Models, Biological; Oxidoreductases, N-Demethylating; Portal Vein; Protein Binding; Rats; Rats, Sprague-Dawley; Tissue Distribution	2001
Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clinical pharmacology and therapeutics, 2004, Volume: 76, Issue:2 Topics: Adult; Asian People; Biological Availability; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genetic Variation; Genotype; Humans; Infusions, Intravenous; Itraconazole; Male; Metabolic Clearance Rate; Midazolam; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Rifampin; Sensitivity and Specificity	2004
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug metabolism and disposition: the biological fate of chemicals, 2004, Volume: 32, Issue:12 Topics: Animals; Antifungal Agents; Baculoviridae; Biotransformation; Cell Line; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochromes b5; Flunitrazepam; Humans; In Vitro Techniques; Insecta; Isoenzymes; Itraconazole; Kinetics; Liver; Microsomes, Liver; Midazolam; Pharmaceutical Preparations	2004
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic & clinical pharmacology & toxicology, 2005, Volume: 97, Issue:4 Topics: Aryl Hydrocarbon Hydroxylases; Bezafibrate; Carbamates; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hypoglycemic Agents; In Vitro Techniques; Itraconazole; Microsomes, Liver; Midazolam; Paclitaxel; Piperidines; Quercetin; Rifampin	2005
Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theoretical biology & medical modelling, 2007, Mar-26, Volume: 4 Topics: Anesthetics, Intravenous; Antifungal Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Forecasting; Humans; Itraconazole; Midazolam; Models, Biological	2007
Increased hepatic cytochrome P4503A activity decreases the risk of developing steroid-induced osteonecrosis in a rabbit model. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2008, Volume: 26, Issue:1 Topics: Anesthetics, Intravenous; Animals; Antifungal Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Enzyme Induction; Excitatory Amino Acid Antagonists; Female; Femur Head Necrosis; Glucocorticoids; Incidence; Itraconazole; Liver; Methylprednisolone; Midazolam; Phenobarbital; Prevalence; Rabbits; Risk Factors	2008
Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:3 Topics: Antifungal Agents; Azoles; Binding Sites; Catalytic Domain; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dioxolanes; Female; Heme; Humans; Hydroxylation; Iron; Itraconazole; Male; Metabolic Networks and Pathways; Midazolam; Stereoisomerism; Triazoles	2012
Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions. Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:8 Topics: Biocatalysis; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Genotype; Humans; Itraconazole; Ketoconazole; Male; Microsomes, Liver; Midazolam; Terfenadine; Testosterone; Vincristine	2013
Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used? Journal of clinical pharmacology, 2014, Volume: 54, Issue:3 Topics: Adult; Area Under Curve; Biomedical Research; Caffeine; Child; Child, Preschool; Female; Humans; Ibuprofen; Infant; Infant, Newborn; Itraconazole; Male; Midazolam; Models, Biological; Pharmacokinetics; Sample Size; Theophylline	2014
An erythematous mass on the lip of a guinea pig (Cavia porcellus). Lab animal, 2014, Volume: 43, Issue:1 Topics: Animals; Diagnosis, Differential; Guinea Pigs; Hemangioma; Itraconazole; Ivermectin; Lip; Male; Midazolam; Pets; Rodent Diseases; Treatment Outcome	2014
Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction. Clinical pharmacokinetics, 2016, Volume: 55, Issue:6 Topics: Computer Simulation; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Fasting; Humans; Itraconazole; Midazolam; Models, Biological	2016
Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions. Drug metabolism and disposition: the biological fate of chemicals, 2018, Volume: 46, Issue:10 Topics: Animals; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Itraconazole; Male; Midazolam; Protein Binding; Rats; Rats, Wistar	2018
PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin. CPT: pharmacometrics & systems pharmacology, 2018, Volume: 7, Issue:10 Topics: Alfentanil; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Humans; Itraconazole; Midazolam; Models, Biological; Rifampin	2018
Clinical evaluation of the potential drug-drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam. British journal of clinical pharmacology, 2022, Volume: 88, Issue:2 Topics: Area Under Curve; Cytochrome P-450 CYP3A; Drug Interactions; Famotidine; Humans; Itraconazole; Male; Midazolam; Pyrazines; Rifampin; Triazines	2022
Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers. Clinical pharmacokinetics, 2022, Volume: 61, Issue:10 Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Digoxin; Drug Interactions; Gemfibrozil; Healthy Volunteers; Humans; Itraconazole; Midazolam; Oxazoles; Pyridines; Quinazolines; Rifampin; Tolbutamide	2022
Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters. Clinical and translational science, 2023, Volume: 16, Issue:4 Topics: Cimetidine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Humans; Itraconazole; Membrane Transport Proteins; Midazolam; Models, Biological; Pharmaceutical Preparations; Rifampin	2023
Evaluation of the Cytochrome P450 3A and P-glycoprotein Drug-Drug Interaction Potential of Futibatinib. Clinical pharmacology in drug development, 2023, Volume: 12, Issue:10 Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Drug Interactions; Humans; Itraconazole; Midazolam; Rifampin	2023